A pre-existing enhancement of COX activation in active RR-MS patients is thus likely to lower IDO expression and thereby prevent an immune therapeutic effect of BAs in these patients, while in the NEDA patients, the lower COX activity allows BAs to take effect. Here, IDO1 is linked to myeloid sarcoma.